Mouse FXII ELISA kit (total FXII antigen)

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Factor XII also known as FXII or Hageman factor is a serine protease and a coagulation factor that plays an important role in initiating the intrinsic pathway of blood coagulation. It has a molecular mass of approximately 80 kDa. The liver primarily synthesizes this protein and it circulates in the blood plasma as an inactive precursor. When activated to Factor XIIa it cleaves and activates other coagulation factors such as Factor XI to propagate the coagulation cascade that helps in blood clot formation.

Biological function summary

This protein helps control blood coagulation processes as part of a larger network of interacting proteins that includes contact activation factors. Factor XII activates not only the coagulation cascade but also pathways involved in fibrinolysis inflammation and bradykinin formation. It triggers the kallikrein-kinin system and leads to the generation of bradykinin a peptide known to induce vascular permeability and inflammation.

Pathways

The involvement of Factor XII spans the intrinsic coagulation pathway and the kallikrein-kinin system. It interacts with several other coagulation factors such as Factor XI and prekallikrein to advance the clotting process. The protein initiates the intrinsic blood coagulation pathway by converting Factor XI to Factor XIa in the presence of negatively charged surfaces. It links to the fibrinolytic pathway and can indirectly activate plasminogen through interactions that generate plasmin.

Associated diseases and disorders

Factor XII deficiency leads to increased risk of thrombosis even though such deficiency generally shows no major bleeding symptoms. The target links to hereditary angioedema where dysregulation in the kallikrein-kinin system involves premature bradykinin activity. Factor XII associates with C1-inhibitor a protein playing a regulatory role in preventing excessive bradykinin production which can manifest in clinical symptoms seen in hereditary angioedema patients.